Corinna Haist

Corinna Haist

Auto-generated profile, based on publicly available information

Corinna Haist

Department of Otorhinolaryngology, Head & Neck Surgery, Heinrich Heine University, 40225 Düsseldorf, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Oral Oncology
Verified
Journal Article
Closed access
CHCorinna Haist
Corinna Haist
ESElena Schulte
Elena Schulte
NBNina Bartels
Nina Bartels
ABArthur Bister
Arthur Bister
ZPZoe Poschinski
Zoe Poschinski
HHHelmut Hanenberg
Helmut Hanenberg

11 November 2021 in Molecular Therapy-Oncolytics
Verified
Journal Article
Open access
ABArthur Bister
Arthur Bister
TITabea Ibach
Tabea Ibach
CHCorinna Haist
Corinna Haist
DSDenise Smorra
Denise Smorra
KRKatharina Roellecke
Katharina Roellecke
HHHelmut Hanenberg
Helmut Hanenberg
Immunotherapy including chimeric antigen receptor (CAR) T cell therapy has revolutionized modern cancer therapy and has achieved remarkable remission and survival rates for several malignancies with historically dismal outcomes. The hinge of the CAR connects the antigen binding to the transmembrane domain and can be exploited to confer features to CAR T cells including additional stimulation, targeted elimination or detection and enrichment of the genetically modified cells. For establishing a novel hinge derived from human CD34, we systematically tested CD34 fragments of different lengths, all containing the binding site of the QBend-10 monoclonal antibody, in a FMC63-based CD19 CAR lentiviral construct. A final construct of 99 amino acids called C6 proved to be the best candidate for flow cytometry-based detection of CAR T cells and >95% enrichment of genetically modified T cells on MACS columns. The C6 hinge was functionally indistinguishable from the commonly used CD8α hinge in vitro as well as in in vivo experiments in NSG mice. We also showed that the C6 hinge can be used for a variety of different CARs and mediates high killing efficacy without unspecific activation by target antigen-negative cells, thus making C6 ideally suited as a universal hinge for CARs for clinical applications.